NasdaqCM:IMNMBiotechs
Immunome (IMNM) Is Up 11.4% After CEO Share Buy And Positive Phase III Data - What's Changed
Immunome recently reported positive phase III data for its lead oncology candidate varegacestat and disclosed fresh inducement stock option grants to new employees, while the CEO also purchased US$500,000 of company shares.
Taken together, the encouraging clinical progress, insider share purchase and equity-based hiring incentives highlight management’s confidence in Immunome’s pipeline and growth plans.
We will now examine how the CEO’s recent insider share purchase and advancing oncology...